TL;DR
Commercial life sciences promotion operates under distinct statutory frameworks across the United States and European Union. The duties differ by instrument, product class, format and duty-holder. Several can apply to a single testimonial, KOL video, social reel, podcast or web page. Between late 2024 and late 2026, three regulatory updates altered promotional liability: the U.S. FTC Trade Regulation Rule on Consumer Reviews and Testimonials (16 CFR Part 465) [1], carrying penalties up to $53,088 per knowing violation [2], unchanged for 2026 [3]; the U.S. FDA Clear, Conspicuous, and Neutral (CCN) dual-modality major statement rule (21 CFR § 202.1(e)(1)) [4]; and EU Directive (EU) 2024/825 (EmpCo) [5].
From 2017 through October 26, 2026, FDA's Office of Prescription Drug Promotion (OPDP) issued 120 untitled letters [6]. Annual volume ranged between 2 and 7 letters (2017–2024) before rising to 63 in 2025—driven by 52 letters issued to brand pharmaceutical sponsors on September 9, 2025 [6], the day FDA announced it was issuing approximately 100 cease-and-desist letters to companies with deceptive ads [7]—and continuing with 25 letters through late October 2026 [6].
OPDP recorded 63 untitled letters in 2025, including 52 dated September 9. The 25 letters through October 26, 2026 already exceed each full-year total from 2017–2024.
Excludes formal Warning Letters and CDER compounded-drug telehealth warning letters. 2026 reflects letters posted through October 26, 2026.
U.S. FDA Center for Drug Evaluation and Research, OPDP Untitled Letters Index (n = 120 letters, 2017 through October 26, 2026).
VayoMed recommends three initial safeguards: verify audio-and-text verbatim parity in video risk statements; document that each testimonial comes from a real user, and substantiate that the depicted result is typical or disclose the generally expected result; and institute pre-clearance briefing protocols for executive and clinician media appearances.
Regulatory Jurisdictions, Formats, and Duty-Holders
Determining pre-publication review obligations requires identifying the specific legal authority, product classification, media format, and statutory duty-holder. In commercial practice, multiple statutory frameworks frequently apply to the same promotional campaign.
Use the product, format and duty-holder columns to identify the provisions that apply to each asset.
| Regime & Governing Authority | Legal Character & Duty-Holder | Governed Product Class & Formats | Enforcement or Penalties | Dates and Milestones |
|---|---|---|---|---|
| US FTC 16 CFR Part 465 (Consumer Reviews & Testimonials) | Trade Regulation Rule; binds commercial sellers, review creators, and brokers | Medical devices, diagnostics, OTC health products, consumer reviews and testimonials | Civil penalties up to $53,088 per violation for knowing violations under 15 U.S.C. § 45(m)(1)(A) | Effective October 21, 2024; 10-company staff warning wave December 22, 2025 |
| US FTC 16 CFR Part 255 (Endorsement Guides) | Interpretive guidance; enforcement is under Section 5 | All commercial health advertising, expert endorsers, KOL videos, atypical patient claims | FTC Act Section 5 administrative cease-and-desist orders, federal court injunctions, and consumer redress | Revised Final Guides effective July 26, 2023 (88 FR 48092) |
| US FDA 21 CFR § 202.1(e)(1) (Major Statement CCN Rule) | Federal Regulation; binds prescription drug applicants and sponsors | Direct-to-consumer prescription drug ads in TV or radio format stating name and indications | FD&C Act Section 502(a)/(n) misbranding notices (untitled and warning letters), federal court injunctions, seizures | Compliance mandatory November 20, 2024; Vanda CCN citation October 26, 2026 |
| US FDA 21 CFR § 801.4 (Intended-Use Doctrine) | Federal Regulation; binds medical device and diagnostic labelers and sponsors | Medical devices, IVDs, RUO systems, clinical customer stories, executive interviews | Adulteration (§ 501(f)(1)(B)) and misbranding (§ 502(o)); warning letters, seizures, civil injunctions | Final Intended Use Rule August 2, 2021 (86 FR 41383) |
| EU EmpCo Directive (EU) 2024/825 & Omnibus 2019/2161 | EU directives implemented through applicable national measures for business-to-consumer practices. | Consumer health devices, OTC diagnostics, wellness apps; uncertified green labels, reviews | National transposing laws. Floor on maximum fines of at least 4% of annual turnover in the affected Member States for coordinated actions under UCPD Article 13(3). | EmpCo dates: national measures due March 27, 2026; Member States required to apply them from September 27, 2026. |
| EU Directive 2001/83/EC (Title VIII Advertising) | EU directive addressed to Member States. Duties on marketing-authorisation holders and other advertisers arise under national transposing law. | Advertising medicinal products. Article 88 covers promotion to the public. | Set by national law (Directive 2001/83/EC Articles 97 and 99). | Directive adopted November 6, 2001. |
| EU MDR/IVDR Article 7 & DSA Article 26 | EU regulations, directly applicable. MDR and IVDR Article 7 covers labelling, making available, putting into service and advertising. DSA Article 26 binds online platform providers. | MDR/IVDR: all device advertising (B2B/B2C). DSA: platform transparency and health profiling | MDR/IVDR: market surveillance by national competent authorities and penalties set by national law. DSA: fines up to 6% of annual worldwide turnover under Article 52 for providers in scope. | General application: MDR May 26, 2021; IVDR May 26, 2022; DSA February 17, 2024. |
U.S. FTC 16 CFR Parts 255 & 465; U.S. FDA 21 CFR § 202.1(e)(1) & § 801.4; EU Directives 2001/83/EC, 2005/29/EC, & (EU) 2024/825; Regulations (EU) 2017/745, (EU) 2017/746, & (EU) 2022/2065. Directive 2001/83/EC Arts. 97 and 99; MDR Arts. 93–97 and 113; IVDR Arts. 88–92 and 106.
Division of Authority: The 1971 FDA-FTC Memorandum of Understanding
In the United States, jurisdiction over healthcare product promotion is apportioned between the FDA and the FTC pursuant to a longstanding Memorandum of Understanding (MOU 225-71-8003) [8]. Under the terms of the MOU:
- FTC Jurisdiction. The FTC maintains primary responsibility for the truth or falsity of advertising (other than labeling) of foods, drugs (with the exception of prescription drugs), medical devices, and cosmetics [8]. The MOU assigns the FTC baseline advertising authority over medical devices generally under Sections 5 and 12 of the FTC Act (15 U.S.C. §§ 45, 52).
- FDA Jurisdiction. The FDA maintains primary responsibility for the labeling of foods, drugs, medical devices, and cosmetics, as well as the advertising of prescription drugs under Section 502(n) of the Federal Food, Drug, and Cosmetic Act (FD&C Act, 21 U.S.C. § 352(n)) [8]. In addition, under Sections 502(q) and 502(r) of the FD&C Act (21 U.S.C. § 352(q), (r)) [9], FDA regulates advertising for restricted medical devices, establishing direct advertising oversight for devices restricted by regulation under Section 520(e) or premarket approval order.
While FDA focuses on whether promotional matter establishes an unapproved intended use or fails to present balanced safety information, the FTC polices unfair or deceptive commercial practices, undisclosed financial connections, and fabricated social endorsements [1], [8], [10]. Consequently, an advertisement for an over-the-counter medical device or diagnostic assay may comply with FDA labeling boundaries yet be deceptive under Section 5, as the Endorsement Guides interpret it, if an endorsing clinician fails to disclose an advisory retainer or equity grant [1], [8], [10].
Television- or Radio-Format Advertisements vs. Other Digital Video Formats
The CCN rule applies to covered direct-to-consumer prescription drug ads in television or radio format. The concurrent text and audio standard applies to television-format ads [4].
FDA explains on page 80963 that the communication attributes addressed by the standards “do not turn on the delivery technology.” The rule and guide leave individual online-video format determinations to the facts. Have regulatory counsel classify the asset [4] [11].
In the six letters compared here, the Vanda and Wegovy television ads drew citations to § 202.1(e)(1), and the CSL Behring television letter used a cf. signal for that provision. The Evolus Reel letter cited § 202.1(e)(5) and (e)(7)(viii). The Pfizer Facebook and Ozempic online-video letters listed no CFR provision [12] [13] [14] [15] [16] [17]. For video outside television or radio format, assess the general advertising requirements of § 202.1(e) and FD&C Act § 502(n) [9] [18]. VayoMed recommends a timed text-and-audio comparison for every promotional video that carries risk information. Outside television or radio format, the firm decides how far to apply this internal benchmark.
Media Format Distinctions and Duty-Holders
Regulatory obligations differ based on product classification and the institutional identity of the duty-holder:
- Prescription Products vs. Medical Devices and IVDs. Postmarketing submission of promotional labeling under Form FDA 2253 is a specific regulatory duty for prescription human drugs under 21 CFR § 314.81(b)(3)(i) [19] and licensed biologics under 21 CFR § 601.12(f)(4) [20]. In contrast, medical device and in vitro diagnostic (IVD) marketing materials, customer case studies, and executive interviews are evaluated under the intended-use doctrine of 21 CFR § 801.4 [21].
- European Union Commercial Boundaries. In the European Union, Member States must prohibit advertising of prescription-only medicinal products to the public under Directive 2001/83/EC Article 88(1)(a) [22]. General consumer protection directives, including the Unfair Commercial Practices Directive (Directive 2005/29/EC) [23] and its amending instruments under Directive (EU) 2019/2161 and Directive (EU) 2024/825 (EmpCo) [24], govern Business-to-Consumer (B2C) commercial practices only. Directive 2006/114/EC and national commercial codes govern misleading and comparative advertising in institutional B2B promotion [25]. Sector-specific medical device rules under Article 7 of the Medical Devices Regulation (MDR, Regulation (EU) 2017/745) [26] and In Vitro Diagnostic Medical Devices Regulation (IVDR, Regulation (EU) 2017/746) [27] apply a media-neutral prohibition on misleading claims across both professional and consumer audiences.
- Platform Providers vs. Commercial Advertisers. Article 26 of the Digital Services Act (Regulation (EU) 2022/2065) imposes advertising transparency and health-profiling prohibitions on providers of online platforms [28], rather than directly on life sciences advertisers. Commercial advertisers encounter these rules through platform ad-buying restrictions, while direct responsibility for tracking pixels placed on a manufacturer's own website is governed by the General Data Protection Regulation (GDPR, Regulation (EU) 2016/679) [29] and the ePrivacy Directive (Directive 2002/58/EC) [30].
Several foundational topics sit outside the operational boundary of this report because dedicated VayoMed studies address them in detail: FDA cleared versus approved claim boundaries, EU AI Act Article 50 transparency labeling, FDA scientific information on unapproved uses (SIUU) communications, and cross-border UDI product identity governance.
FTC Oversight: The Consumer Review Rule and the Endorsement Guides
The FTC exercises primary and parallel enforcement authority over commercial claims, customer reviews, and influencer marketing across medical devices, diagnostics, clinical laboratory services, dietary products, and DTC digital health applications [1], [8], [10].
The Trade Regulation Rule on Consumer Reviews and Testimonials (16 CFR Part 465)
Promulgated on August 22, 2024 (89 FR 68034) with an effective date of October 21, 2024, the FTC Trade Regulation Rule on the Use of Consumer Reviews and Testimonials codifies specific unfair or deceptive practices into federal regulation [1]. Promulgation as a trade regulation rule alters FTC enforcement authority: previously, obtaining monetary civil penalties against a first-time violator required prior administrative cease-and-desist orders or specific Notice of Penalty Offenses service. Under 16 CFR Part 465, the Commission is authorized to seek federal court civil penalties under Section 5(m)(1)(A) of the FTC Act (15 U.S.C. § 45(m)(1)(A)) [1], [2].
Under 16 CFR § 1.98(d), as adjusted for statutory inflation on January 17, 2025 (90 FR 5580), the civil penalty ceiling stands at up to $53,088 per violation for knowing violations [2]. On September 15, 2026 (91 FR 58446), implementing Office of Management and Budget Memorandum M-26-11, the FTC maintained all existing 2025 civil penalty ceilings unchanged for 2026 [3]. The rule authorizes courts to impose civil penalties only for knowing violations under Section 5(m)(1)(A), which requires demonstrating that the party acted with "actual knowledge or knowledge fairly implied on the basis of objective circumstances that such act is unfair or deceptive and is prohibited by such rule" [1], [2], [31]. In the rulemaking preamble, the Commission noted that courts decide how to calculate the number of violations in a given case and retain statutory discretion under 15 U.S.C. § 45(m)(1)(C) to impose lower per-violation penalties after evaluating mitigating factors such as degree of culpability, history of prior conduct, ability to pay, and effect on ability to continue doing business [1].
On December 22, 2025, FTC staff issued warning letters to 10 companies regarding potential non-compliance with the Consumer Review Rule [32]. The FTC expressly noted that these letters represented staff warnings regarding potential compliance obligations rather than formal Commission determinations of violation [32].
The provisions most relevant to life sciences commercial teams define specific boundaries that must be incorporated into review workflows [1]:
| 16 CFR Part 465 Provision | Regulated Conduct | Knowledge Element or Condition | Practical Life Sciences Scenario |
|---|---|---|---|
| § 465.2(a) | Creating, writing, or selling a fake consumer review, consumer testimonial, or celebrity testimonial (including AI-generated personas) | None stated in § 465.2(a). Civil penalties under 15 U.S.C. § 45(m)(1)(A) carry a separate knowledge requirement [1] | Marketing teams utilizing generative AI tools to generate composite patient quotes or fictitious clinician user profiles for product landing pages [1] |
| § 465.2(b) | Purchasing a consumer review or disseminating, or causing the dissemination of, a consumer or celebrity testimonial that materially misrepresents the person's existence, use or experience | The business knew or should have known of the misrepresentation [1] | Paying to distribute a patient video in which an actor falsely claims to have used a product |
| § 465.2(c) | Procuring a materially false consumer review from an officer, manager, employee, agent or their immediate relative for posting on a third-party platform | The business knew or should have known of the misrepresentation [1] | Asking an employee to post an invented experience with the company's diagnostic product on an independent review site |
| § 465.4 | Providing compensation or incentives conditioned expressly or implicitly on the sentiment of a consumer review (applies to consumer reviews) | None stated. Compensation must be conditioned on sentiment [1], [31] | Offering discounts on diagnostic test cartridges or device accessories on the condition that the customer submits a five-star review on an e-commerce platform [1] |
| § 465.5(a) | An officer or manager creates a review or testimonial about the business or its offering without clear and conspicuous disclosure of the material relationship | For a testimonial, the exception applies when the relationship is otherwise clear to the audience [1] | A company executive posts a consumer review without disclosing the executive relationship. |
| § 465.5(b) | A business disseminates a testimonial by an officer, manager, employee or agent without clear and conspicuous disclosure | Applies where the relationship is otherwise unclear and the business knew or should have known it. Exceptions include generalized purchaser solicitations and merely hosting reviews [1] | A business distributes a product testimonial by an employee whose employment is undisclosed and otherwise unclear. |
| § 465.5(c) | An officer or manager solicits a review from covered insiders or relatives, and the request results in an undisclosed review | Applies when the officer or manager discourages disclosure, fails to instruct on disclosure, or knows or should know of nondisclosure and fails to take remedial steps. Generalized purchaser solicitations are excepted [1] | A manager directs employees to post consumer reviews without instructing them to disclose their employment. |
| § 465.6 | Misrepresenting that a company-controlled website, organization, or forum "provides independent reviews or opinions, other than consumer reviews, about a category of businesses, products, or services" | None stated. The entity must be controlled by the business and its independence misrepresented [1] | Establishing a manufacturer-controlled diagnostic assessment portal presented to patients as an independent clinical ranking board [1] |
| § 465.7(a) | Suppressing reviews through unfounded or groundless legal threats, physical threats, intimidation or public accusations made with knowledge of falsity or reckless disregard | Knowledge or reckless disregard applies to the falsity of a public accusation. The other conduct has its own elements [1] | An unfounded litigation threat to force removal of a patient’s negative review |
| § 465.7(b) | Misrepresenting that consumer reviews displayed in a dedicated review section represent most or all submitted reviews, when negative reviews have been suppressed | The reviews were suppressed based on ratings or negative sentiment and the business materially misrepresents their completeness [1] | Gating an online clinic-feedback portal to display only reviews rating the device four stars or higher while claiming the section reflects all patient feedback [1] |
| § 465.8 | Purchasing, selling, or procuring fake social-media indicators (such as bot followers or artificial video views) to misrepresent commercial influence | Requires showing that the business knew or should have known that the indicators were artificially generated [1] | Procuring automated view packages or synthetic follower counts for a newly established brand channel to imply widespread clinical adoption [1] |
In the rulemaking record for 89 FR 68034, the Commission addressed the scope of Part 465 regarding business-to-business transactions [1]. The Commission declined requests to add businesses and public-sector entities to consumer definitions, and explained that the testimonial provisions concern individual endorsements while excluding endorsements by entities [1]. The rule's application to testimonials by individual clinicians who have used a product is not expressly addressed in the text; life sciences commercial teams should treat individual clinician testimonials as potentially covered under Part 465 and in any event subject to the FTC Endorsement Guides and Section 5 of the FTC Act [1], [10].
The FTC Endorsement Guides (16 CFR Part 255): Administrative Interpretations and Disclosure Standards
While 16 CFR Part 465 governs fabricated, incentivized, suppressed, or covertly controlled reviews, the substantive standards for legitimate endorsements are established in the FTC Guides Concerning the Use of Endorsements and Testimonials in Advertising (16 CFR Part 255, revised July 26, 2023 under 88 FR 48092) [10].
Under 16 CFR § 255.0(a), the Endorsement Guides represent administrative interpretations of Section 5 of the FTC Act (15 U.S.C. § 45) [10]. The Guides carry no civil penalties of their own; rather, practices inconsistent with the Guides may lead the Commission to initiate administrative or judicial proceedings under Section 5 for unfair or deceptive acts or practices [10].
Three provisions in Part 255 define the baseline for life sciences marketing:
- Clear and Conspicuous Modality Matching (§ 255.0(f)). The Guides state that disclosures should match the delivery medium [10]. The Guides recommend an audible disclosure for audio, a visible disclosure for visual content, and disclosure in both the audio and visual portions when the representation uses both. The Guides say simultaneous presentation is more likely to be clear and conspicuous [10]. In interactive digital media, disclosures should be unavoidable [10].
- Consumer experience and typicality (§ 255.2(b)). Review whether the ad implies that consumers can generally expect the depicted results. Substantiate that the depicted results are typical or disclose the generally expected result clearly and conspicuously in the depicted circumstances [10]. FTC staff identifies “Results not typical” and “Individual results may vary” as insufficient to change that impression [33].
- Expert Endorsers and Material Connections (§§ 255.3, 255.5). Under § 255.3, an expert endorser must possess qualifications sufficient to give an expert opinion and must have evaluated the product using methods that someone with equivalent expertise would employ [10]. Under § 255.5, advertisers must disclose any connection between the endorser and the seller that might materially affect the weight or credibility of the endorsement and that a reasonable audience would find unexpected [10]. In life sciences marketing, VayoMed advises that material connections requiring disclosure include speaker bureau honoraria, research funding, paid consulting agreements, travel reimbursements, and loaned medical equipment.
FTC staff's Health Products Compliance Guidance states that health benefit claims require competent and reliable scientific evidence. For many health-related efficacy claims, staff expects appropriately designed randomized controlled human clinical testing [34].
FTC staff says a required disclosure should appear without having to select “more,” that a profile-page mention is insufficient, and that a disclosure only at the end of a video is likely to be missed. In a Story, staff recommends making the disclosure easy to notice and read in the time available [33].
FDA Prescription Drug Promotion: The CCN Dual-Modality Rule and Digital Enforcement
Prescription drug and biologic marketing operates under direct statutory oversight by FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) under Section 502(n) of the FD&C Act (21 U.S.C. § 352(n)) [4]. On November 21, 2023, FDA finalized its Clear, Conspicuous, and Neutral (CCN) major statement regulation (88 FR 80958, codified at 21 CFR § 202.1(e)(1)), with mandatory compliance beginning on November 20, 2024 [4].
The Clear, Conspicuous, and Neutral (CCN) Standards (21 CFR § 202.1(e)(1))
Under 21 CFR § 202.1(e)(1), direct-to-consumer prescription drug advertisements presented in television or radio format that state the drug's name and conditions of use must present the major statement relating to side effects and contraindications in a clear, conspicuous, and neutral manner [4]. The regulation enumerates five distinct standards under § 202.1(e)(1)(ii)(A) through (E) [4]:
- Standard (A) (Consumer-Friendly Language). The major statement must be presented in consumer-friendly language and terminology that is readily understandable by the general public [4].
- Standard (B) (Audio Understandability). The major statement’s audio must be at least as understandable as the audio in the rest of the ad, considering volume, articulation and pacing [4].
- Standard (C) (Dual-Modality Presentation for Television Format). For television-format advertisements, the major statement must be presented concurrently in both audio and text (visual display) [4]. Under § 202.1(e)(1)(ii)(C)(1), the visual text must display either the verbatim key terms or phrases corresponding to the spoken statement, or the verbatim complete transcript of the spoken statement [4]. In its Small Entity Compliance Guide (88 FR 89303, December 2023), FDA notes that the onscreen text must display the same words as the corresponding spoken statement rather than synonyms or rephrased terminology [11]. Under § 202.1(e)(1)(ii)(C)(2), the display must appear for a duration sufficient to allow the viewer easily to read it [4].
- Standard (D) (Visual Typography and Contrast). For television-format advertisements, the visual display must be formatted with appropriate font style, size, and contrast against the background, and placed on screen so that it can be read easily [4].
- Standard (E) (Distraction Standard). During the presentation of the major statement, the advertisement must present the statement free of audio or visual elements likely to interfere with comprehension [4]. In the Small Entity Compliance Guide, FDA explicitly states that the standard "does not categorically prohibit" creative elements such as music, sound effects, drawings, and humor [11]. Rather, the agency evaluates whether the creative elements in context are likely to distract viewer attention and interfere with comprehension [11].
Apply the standards relevant to the television or radio format of a covered ad [4] [11].
On September 9, 2025, FDA announced it was “initiating rulemaking to close the adequate provision loophole” [7]. The 2026 Unified Agenda entry for RIN 0910-AJ14, checked November 13, 2026, targets December 2026 for a proposal to remove the adequate-provision option for satisfying the brief-summary requirement in broadcast ads and shows a blank Federal Register citation [35]. A Federal Register search by this RIN on the same date returned zero documents.
Verified FDA Enforcement Actions in Digital Video and Social Channels (2021–2026)
FDA's Regulatory Procedures Manual treats warning and untitled letters as advisory correspondence. Warning letters address violations FDA considers significant and seek prompt voluntary compliance. Untitled letters generally address violations below the warning-letter threshold [36]. The allegations in these letters are presented as the agency's positions before adjudication. The cases show the media, claims and provisions each letter cites.
In the six video letters in the first six rows, Vanda and Wegovy cite the CCN provision, CSL Behring uses a cf. signal, Evolus cites the general advertising provisions listed, and Pfizer and Ozempic list no CFR provision.
| Company, Product & Date | FDA Center & Action Type | Promotional Asset & Medium | Key Statutory & Regulatory Provisions Cited |
|---|---|---|---|
| Vanda Pharmaceuticals (NEREUS, 10/26/2026) | CDER OPDP Untitled Letter | DTC Broadcast Television Ad (31s major statement, NER0009) | FD&C Act § 502(n); 21 CFR § 202.1(e)(1)(ii)(C), (E), (e)(5) |
| Evolus, Inc. (JEUVEAU, 09/28/2026) | CDER OPDP Untitled Letter | Instagram Reels (@evolus, @jeuveaubyevolus) featuring patient testimonial | FD&C Act § 502(a), (n); 21 CFR § 202.1(e)(5), (e)(7)(viii) |
| Pfizer, Inc. (ADCETRIS, 04/08/2026) | CDER OPDP Untitled Letter | Facebook Video Ads Set (PTCL Video ads 1 to 3) | FD&C Act misbranding (no CFR subsections enumerated) |
| Novo Nordisk Inc. (OZEMPIC, 02/26/2026) | CDER OPDP Untitled Letter | Online Video ('Random Guy OLV' skit) | FD&C Act misbranding (no CFR subsections enumerated) |
| Novo Nordisk Inc. (WEGOVY, 02/05/2026) | CDER OPDP Untitled Letter | DTC Broadcast Television Commercial ('January 2026 Pill Spot', US25SEMO01839) | FD&C Act § 502(a), (n); 21 CFR § 202.1(e)(1)(ii)(C), (e)(5) |
| CSL Behring (HIZENTRA, 09/09/2025) | CBER Warning Letter 716297 | Consumer Broadcast Television Commercial | FD&C Act § 502(n); cf. 21 CFR § 202.1(e)(1), (e)(5) |
| ImmunityBio / Altor (ANKTIVA, 03/13/2026) | CDER OPDP Warning Letter 725468 | Broadcast commercial and website link to external podcast (Sean Spicer Show) | FD&C Act §§ 502(a), (n), 502(f)(1); 21 CFR §§ 201.128, 202.1(e)(5), 314.81(b)(3)(i) |
| Sprout Pharmaceuticals (ADDYI, 05/29/2025) | CDER OPDP Warning Letter 709942 | CEO Personal Instagram Account (@cindypinkceo) | FD&C Act § 502(a), (n); 21 CFR §§ 202.1(e)(3)(ii), (iii), (e)(5), 314.81(b)(3)(i) |
| ExThera Medical (Extracorporeal Filters, 02/06/2026) | CDRH Warning Letter 715068 | CMO podcast, conference video, and Vimeo promotional clip | FD&C Act §§ 501(f)(1)(B), 502(o), 502(a); cf. 21 CFR § 812.7 |
| Agena Bioscience (MassARRAY4 IVD, 03/21/2024) | CDRH Warning Letter 665159 | Corporate website customer stories and CEO press quote | FD&C Act §§ 501(f)(1)(B), 502(o); 21 CFR § 809.10(c) |
| Anne's Daye Ltd (Tampons & Screening Kits, 12/17/2024) | CDRH Warning Letter 696362 | Product website, retail listings, and founder interview | FD&C Act §§ 501(f)(1)(B), 502(o); 21 CFR § 807.81(a)(3) |
| Estar Technologies (PRP Devices, 04/22/2026) | CBER Warning Letter 716831 | Company websites (estar-medical.com, tropocells.com) | FD&C Act §§ 501(f)(1)(B), 502(o); 21 CFR § 807.81(a)(3) |
| CytoDyn (leronlimab, 02/11/2022) | CDER OPDP Warning Letter 626957 | Corporate link to an external CEO interview about an investigational drug | 21 CFR § 312.7(a) |
| CooperSurgical (Paragard, 02/12/2021) | CDER OPDP Warning Letter 613339 | Sponsored lifestyle segment on WBTS The Hub Today | 21 CFR §§ 202.1(e)(5) and 314.81(b)(3)(i) |
U.S. FDA OPDP, CBER, and CDRH enforcement letters (2021 through October 2026 full-text review).
1. Vanda Pharmaceuticals, Inc. (October 26, 2026 CDER OPDP Untitled Letter, NDA 220152, NEREUS)
OPDP reviewed a direct-to-consumer broadcast television advertisement (NER0009) for NEREUS, submitted under cover of Form FDA 2253 and flagged in part through complaints submitted to the FDA Bad Ad Program [37] [12]. OPDP timed the major statement from 0:19 to 0:50. It cited two defects under 21 CFR § 202.1(e)(1) and made a separate misleading-impression finding [12]:
- Audio-SUPER Text Divergence. At timestamp 0:41, the voiceover stated, "Strong CYP3A4 inhibitors may increase Nereus levels and the risk of side effects. Tell your healthcare provider about all the medicines you're taking," whereas the onscreen SUPER text stated, "Medications that are strong CYP3A4 inhibitors may increase Nereus levels and the risk of side effects. Nereus has not been studied in people with severe kidney or liver impairment." OPDP stated that displaying information in the visual text that was absent from the concurrent spoken statement failed the dual-modality requirement of 21 CFR § 202.1(e)(1)(ii)(C) [12].
- Competing Action Distractions. During the 31-second major statement, the visual sequence cut through 11 dynamic scene changes depicting a man driving a convertible in a rapid car-and-motorboat pursuit sequence [12]. OPDP cited 21 CFR § 202.1(e)(1)(ii)(E), stating that the rapid scene cuts and action narrative distracted viewer attention from the safety information [12].
- Driving warnings and timing. The driving warning appeared in both audio and text. OPDP said the chase implied that treatment “will not inhibit one’s ability to drive, even at extreme levels.” It said the warning was insufficient to offset the impression about driving and machinery, especially while the audience saw the extreme driving. The sequence also suggested instant efficacy and use after motion had begun. The label advises dosing “approximately 60 minutes before an event expected to cause vomiting induced by motion” [12].
2. Evolus, Inc. (September 28, 2026 CDER OPDP Untitled Letter, BLA 761085, JEUVEAU)
OPDP reviewed promotional social media materials submitted by Evolus under cover of Form FDA 2253, alongside a complaint received through the Bad Ad Program [37], [13]. The materials included an Instagram Reel published on company handles @evolus and @jeuveaubyevolus, featuring an interview with a patient named Josephine [13]. The speaker stated: "I feel really good. I'm really surprised at how quickly it's kicking in! And I'm feeling like the line between my eyebrows is gone." [13]. OPDP identified several promotional defects [13]:
- Atypicality disclaimers. OPDP said the testimonial may have reflected the patient’s experience and gave inadequate support for implying a similar response in other patients. OPDP said the variation subtitle did not offset the post’s misleading impression about the magnitude and onset of efficacy. It also said the record did not substantiate claims that lines were “gone” or that results were “complete” [13].
- Endpoint Conflation. The video suggested rapid efficacy based on exploratory Day 2 onset data (a 1-point improvement on the Glabellar Line Scale), whereas the primary efficacy endpoint evaluated in clinical trials was a composite 2-point improvement at Day 30 assessed by both investigator and subject [13].
- Risk placement. Jeuveau carries a boxed warning. In the Reel, risk information appeared after the brand tagline and a black screen, without a signal that more content followed. The accompanying caption placed it beneath a fold. OPDP cited 21 CFR § 202.1(e)(5) and (e)(7)(viii) [13].
3. Pfizer, Inc. (April 8, 2026 CDER OPDP Untitled Letter, BLA 125388, ADCETRIS)
OPDP cited social media video advertisements disseminated on Facebook, titled "ADCETRIS PTCL Facebook Ads Set" (Video ads 1 through 3), submitted under Form FDA 2253 [14]. The advertisements presented indication claims regarding peripheral T-cell lymphoma (PTCL) without specifying the approved PTCL subtypes [14]. OPDP noted that the full FDA-approved indication was presented at the bottom of the ads after the Important Safety Information (ISI) block, but stated that this "is not sufficient to correct the overall misleading impression created by these claims" [14]. Additionally, OPDP cited the advertisements because they did not communicate the reason for the bleomycin contraindication (due to pulmonary toxicity) and omitted fatal outcomes associated with three warnings [14]. The letter cited FD&C Act misbranding provisions generally without enumerating specific CFR subsections [14].
4. Novo Nordisk Inc. (February 26, 2026 and February 5, 2026 CDER OPDP Untitled Letters)
Two enforcement letters issued to Novo Nordisk in February 2026 illustrate regulatory scrutiny across online video and broadcast television:
- Ozempic Online Video (February 26, 2026). OPDP cited a direct-to-consumer online video (NDA 209637, "Ozempic vs. – Random Guy OLV", US25OZM01130) featuring a character named Stan holding comparative cue cards while the musical refrain "There's Only One Ozempic" played [15]. OPDP cited implied comparative superiority based on dialogue ("I see you don't have as many FDA-approved uses as Ozempic"), bird-call sound exchanges, and contrasting orange versus gray shirts in the absence of head-to-head clinical trial evidence [15]. OPDP stated that displaying full indications in visual SUPER text was "not sufficient to correct" the voiceover claim "most FDA-approved uses" [15]. Furthermore, risk information was placed after the brand logo and jingle without an audio or visual signal; OPDP stated that a statement at the top of the video stating "To see Prescribing Information and Medication Guide, click video, link in this ad, or visit Ozempic-pi.com" "is not sufficient to mitigate the misleading impression" [15]. The letter cited FD&C Act misbranding provisions generally without enumerating CFR subsections [15].
- Oral Wegovy Broadcast Commercial (February 5, 2026). OPDP cited a direct-to-consumer broadcast commercial (NDA 218316, "January 2026 Pill Spot", US25SEMO01839) [16]. OPDP stated that claims such as "live lighter" and "a way forward" suggested emotional, lifestyle, and life-direction benefits that had not been demonstrated by substantial evidence [16]. Furthermore, OPDP cited 21 CFR § 202.1(e)(1)(ii)(C), noting that visual SUPER text contained risk details absent from the concurrent spoken voiceover, failing the dual-modality requirement [16].
5. CSL Behring (September 9, 2025 CBER Warning Letter 716297, BLA 125350/1472, HIZENTRA)
CBER reviewed the direct-to-consumer Hizentra television commercial in its September 9, 2025 letter. CBER said rapid camera cuts and intensifying music during the risk presentation distracted from the major statement, citing 21 CFR § 202.1(e)(1) and (e)(5) with a cf. signal. It also cited claims that overstated effectiveness [17].
6. ImmunityBio, Inc. / Altor BioScience (March 13, 2026 CDER OPDP Warning Letter 725468, BLA 761336, ANKTIVA)
Following prior untitled letters sent to subsidiary Altor BioScience on September 9, 2025 and January 7, 2026—which OPDP described jointly as addressing "both the Healthcare Provider Branded webpage and Consumer webpage for Anktiva"—OPDP issued Warning Letter 725468 after reviewing a broadcast commercial and an external video podcast episode on The Sean Spicer Show featuring Executive Chairman Dr. Patrick Soon-Shiong [38]. ImmunityBio made the podcast accessible through its corporate website [38].
During the podcast, Dr. Soon-Shiong discussed Anktiva's mechanism of action and claimed that the product "can treat all cancers," suggesting utility across oncology indications far beyond its approved indication for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ [38]. OPDP noted that the podcast included no risk information [38]. OPDP cited false and misleading benefit presentation and risk omission under Sections 502(a) and 502(n) of the FD&C Act, failure to provide adequate directions for unapproved new uses under Section 502(f)(1) and 21 CFR § 201.128, and failure to submit the promotional material to FDA under cover of Form FDA 2253 at initial dissemination pursuant to 21 CFR § 314.81(b)(3)(i) [19], [38].
7. Earlier Reference Actions: Executive Accounts, Web Links, and Broadcast Segments (2021–2025)
Three earlier letters identify the specific personal, corporate or sponsored media FDA reviewed.
- Sprout Pharmaceuticals, Inc. (May 29, 2025 OPDP Warning Letter 709942, NDA 022526, ADDYI). OPDP cited product promotional claims posted by Chief Executive Officer Cindy Eckert on her personal Instagram account (@cindypinkceo), flagged through a Bad Ad complaint [37], [39]. OPDP cited omission of the boxed warning regarding severe hypotension and syncope in certain settings, failure to provide fair balance under 21 CFR § 202.1(e)(3)(ii), (iii), and (e)(5), and failure to submit the posting under Form FDA 2253 pursuant to 21 CFR § 314.81(b)(3)(i) [19], [39].
- CytoDyn, Inc. (February 11, 2022 OPDP Warning Letter 626957). OPDP cited CytoDyn for posting a hyperlink on its corporate website to an external media interview on Proactive Media featuring its CEO discussing investigational leronlimab for COVID-19, alleging unapproved pre-approval promotional claims under 21 CFR § 312.7(a) [40].
- CooperSurgical, Inc. (February 12, 2021 OPDP Warning Letter 613339, Paragard, NDA 018680). OPDP cited a sponsored lifestyle television segment on WBTS The Hub Today featuring a guest discussion of Paragard [41]. OPDP stated that the video "fails to communicate any risk information" and that viewers "are referred to 'WWW.PARAGARD.COM' for further information about Paragard; however, this does not mitigate the complete omission of risk information" [41]. The letter cited 21 CFR § 202.1(e)(5) and failure to submit under Form FDA 2253 pursuant to 21 CFR § 314.81(b)(3)(i) [19], [41].
Disclosures and Formatting That FDA Cited as Ineffective
In the five letters below, FDA said that a disclaimer, link or layout feature was insufficient to offset the misleading impression or missing risk information it identified in the main creative.
In these five letters, OPDP said a disclaimer, external reference or later full statement was insufficient to offset the impression created by the main creative or address omitted risks.
| Promotional Asset & Medium | Attempted Mitigating Feature | FDA Evaluated Defect & Finding | Review Takeaway (VayoMed Inference) |
|---|---|---|---|
| Vanda DTC Television Ad (NEREUS, 10/26/2026) | Spoken voiceover and visual SUPER disclaimer stating 'Nereus may impair abilities required for driving a motor vehicle or operating heavy machinery' | OPDP said the warning did not offset the misleading impression about driving while the ad showed extreme driving. It separately cited the rapid scene changes under standard (E) and the unmatched kidney/liver text under standard (C). | Check for visuals that contradict a warning at the same moment. In this letter, the spoken and displayed warning did not offset the driving impression. |
| Evolus Instagram Reel (JEUVEAU, 09/28/2026) | Onscreen SUPER text stating 'Individual results may vary' alongside patient testimonial claiming rapid onset | OPDP said the individual experience gave inadequate support for implying that all patients would respond similarly. The subtitle did not offset the post’s misleading impression about the magnitude and onset of efficacy. | Check whether the evidence supports the size and speed of the implied result. In this letter, the variation subtitle did not offset the impression. |
| Novo Nordisk Online Video (OZEMPIC, 02/26/2026) | Statement at top of video: 'To see Prescribing Information and Medication Guide, click video, link in this ad, or visit Ozempic-pi.com', alongside full indications in SUPERs | OPDP stated the top-of-video statement was not sufficient to mitigate the misleading impression created by placing risk information after the brand logo and jingle; full indications in SUPERs were not sufficient to correct the voiceover claim 'most FDA-approved uses' | Check where risks appear and what comparison the voiceover makes. OPDP said the external reference did not address risk placement and the SUPER text did not correct the most-FDA-approved-uses claim. |
| Pfizer Facebook Video Set (ADCETRIS, 04/08/2026) | Full approved indication presented at the bottom of the ads after the Important Safety Information (ISI) block | OPDP stated presenting the full indication after the ISI was not sufficient to correct the overall misleading impression created by claims that failed to specify approved PTCL subtypes; ads omitted bleomycin pulmonary toxicity rationale and fatal warnings | Check whether the main claim names the approved subtypes. In this letter, the full indication after the safety block did not offset the broader claim. |
| CooperSurgical Broadcast Segment (Paragard, 02/12/2021) | Onscreen referral directing television viewers to 'WWW.PARAGARD.COM' for further information | OPDP stated the broadcast video failed to communicate any risk information, and that referring viewers to the website did not mitigate the complete omission of risk information | Check what the segment itself says about risks. In this letter, the website referral did not address the absence of risk information. |
FDA OPDP enforcement letters (Vanda 2026, Evolus 2026, Pfizer 2026, Novo Nordisk 2026, CooperSurgical 2021).
The cases give reviewers three places to look: the scene that carries the claim, the point where material safety information appears, and the wording viewers see and hear during the major statement. In Vanda, OPDP cited a driving scene despite a driving warning in the same ad [12]. In Ozempic and CooperSurgical, OPDP said an external reference was insufficient to address the risk placement or omission [15] [41]. Pfizer illustrates the need to check the main video’s indication claims, and Vanda and Wegovy illustrate the need to compare spoken and displayed risk terms [14] [12] [16].
Medical Devices and IVDs: Intended-Use Doctrine, Customer Stories, and Executive Media
Medical device and diagnostic manufacturers operate under a statutory framework distinct from prescription drug advertising. Device promotional claims, customer case studies, and executive media interviews are evaluated under the intended-use doctrine of 21 CFR § 801.4 [21].
The Intended-Use Doctrine (21 CFR § 801.4)
Under FDA's August 2, 2021 Final Rule (86 FR 41383, codified at 21 CFR § 801.4), the objective intent of the persons legally responsible for the labeling of a device may be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives [21]. Objective intent may also be shown by circumstances surrounding the distribution of the article or the offering of an article outside its authorized use [21].
Statements made by company executives, clinicians acting on behalf of a sponsor, and featured customers on corporate channels can be evaluated by FDA as objective evidence of intended use [21]. If public statements describe clinical applications exceeding cleared 510(k) indications, De Novo classifications, or Premarket Approvals (PMAs), FDA may determine that the device is an unapproved new device, causing it to be adulterated under Section 501(f)(1)(B) of the FD&C Act (21 U.S.C. § 351(f)(1)(B)) and misbranded under Section 502(o) (21 U.S.C. § 352(o)) [21], [42], [43], [44].
Verified Device Enforcement: Customer Stories, Podcasts, and Executive Claims
In these warning letters, CDRH and CBER cited public media, customer stories and executive statements as evidence of an unapproved intended use.
- Agena Bioscience, Inc. (March 21, 2024 CDRH Warning Letter 665159). Agena marketed its MassARRAY4 platform under Research Use Only (RUO) labeling [42]. CDRH cited a dedicated corporate webpage entitled "FEATURED CUSTOMER STORIES" showcasing customer testimonials describing clinical diagnostic testing, alongside a press release quoting the CEO regarding the platform's selection for a statewide newborn screening program [42]. CDRH stated that these public materials, alongside inspectional findings regarding clinical software deployment, demonstrated an intended clinical diagnostic use, violating RUO labeling requirements under 21 CFR § 809.10(c) and causing the device to be adulterated under Section 501(f)(1)(B) and misbranded under Section 502(o) [42].
- ExThera Medical Corporation (February 6, 2026 CDRH Warning Letter 715068). ExThera held active Investigational Device Exemptions (IDE G210074 and G230144) for blood-purification filtration devices [43]. CDRH cited public media assets representing the investigational device as safe and effective before marketing authorization, including a December 2024 podcast featuring the Chief Medical Officer titled "Shows Promise To End Long COVID", a September 2024 conference video, and a November 2024 promotional video on Vimeo [43]. CDRH cited violations of Sections 501(f)(1)(B), 502(o), and 502(a) of the FD&C Act, while referencing 21 CFR § 812.7 (which prohibits the promotion of an investigational device) as the basis of an earlier FDA request [43].
- Anne's Daye Ltd (December 17, 2024 CDRH Warning Letter 696362). Anne's Daye held 510(k) clearance K223883 for non-medicated menstrual tampons, yet marketed "CBD Daye Tampons" with claims of pain relief across product websites, retail listings, and a published founder interview on startup portal therecursive.com [44]. CDRH also cited diagnostic claims for vaginal microbiome screening kits marketed for diagnosing infections [44]. CDRH cited 21 CFR § 807.81(a)(3) for marketing without a required premarket notification, resulting in adulteration under Section 501(f)(1)(B) and misbranding under Section 502(o) [44].
- Estar Technologies Ltd (April 22, 2026 CBER Warning Letter 716831). CBER reviewed promotional statements on corporate websites estar-medical.com and tropocells.com for platelet-rich plasma (PRP) preparation kits [45]. CBER stated that the websites promoted PRP systems for clinical indications exceeding the scope cleared under 510(k) BK110035, citing 21 CFR § 807.81(a)(3) [45].
FDA's Draft Misinformation Guidance: Nonbinding Status and Concrete Limits
FDA's July 2024 draft guidance, Addressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers (89 FR 56387, Docket FDA-2014-D-0447), offers no safe harbor for rapid rebuttals [46].
In federal administrative law, the status of draft guidance is governed by FDA's Good Guidance Practices regulation (21 CFR § 10.115) [46]. The July 2024 document bears the required agency notices: "Contains Nonbinding Recommendations" and "Draft - Not for Implementation" [46]. Guidance documents describe agency thinking and offer nonbinding recommendations [46]. A draft guidance reflects only tentative agency thinking subject to revision prior to finalization [46].
Inside the July 2024 draft, FDA describes a proposed enforcement policy separating communications into two distinct categories [46]:
- Tailored Responsive Communications. The draft outlines an enforcement policy under which FDA does not intend to enforce applicable promotional labeling, advertising, or postmarketing submission requirements (such as Form FDA 2253 for prescription drugs and biologics), and does not intend to use the response standing alone as evidence of a new intended use, for communications that meet the proposed criteria [46]. Under the draft, a tailored response must address misinformation created by an independent third party (defined as an entity "not acting on behalf of that firm"), must be truthful, non-misleading, and scientifically sound, must be limited to addressing the specific false claim, and, as recommended in Q5, should provide a mechanism for obtaining current FDA-required labeling, including FDA-approved patient labeling if any [46].
- General Medical Product Communications. The draft distinguishes tailored responses from broader educational communications that provide general scientific context [46]. General medical product communications remain fully subject to standard promotional labeling, advertising, fair balance, and Form FDA 2253 submission requirements whenever they cross into promotional territory [46].
For commercial teams evaluating digital social strategies, the draft contains several explicit limitations [46]:
- Exclusion of Opinions and Value Statements. The proposed enforcement policy excludes responses to opinions and value statements [46].
- Exclusion of Individual Patient Experiences. For testimonial governance, the draft explicitly states that the proposed enforcement policy excludes responses about an individual patient's experience [46].
- Exclusion of Broadcast Formats. The proposed enforcement policy excludes television and radio advertisements [46].
VayoMed recommends checking who commissioned, scripted or controlled a creator's content before treating it as independent under the draft. Payment or other benefits also warrant separate review of the FTC Guides' material-connection analysis [46] [10].
A promotional reply remains subject to the usual requirements [46].
European Union Cross-Border Advertising Requirements
Global life sciences organizations marketing products across European Member States face a multi-layered legal regime combining sector-specific healthcare directives, general consumer protection law, and platform regulations.
Scope, Competence, and the Prescription Drug Advertising Prohibition
Member States must prohibit advertising prescription-only medicinal products to the public under Article 88(1)(a) of Directive 2001/83/EC. Article 88(4) exempts industry vaccination campaigns approved by national authorities. For non-prescription products that may be advertised to the public, Article 90 prohibits references to recommendations by scientists, healthcare professionals or celebrities (f), case histories likely to lead to erroneous self-diagnosis (i), and improper, alarming or misleading claims of recovery (j) [22].
For medical devices, in vitro diagnostics, and consumer health products, European advertising law operates across two distinct domains:
- B2C Consumer Protection Directives. The Unfair Commercial Practices Directive (Directive 2005/29/EC) [23] and its amending instruments (Directive (EU) 2019/2161 and Directive (EU) 2024/825) [24] apply to Business-to-Consumer (B2C) commercial practices. Institutional B2B sales of medical capital equipment, diagnostic platforms to clinical laboratories, or bioprocessing consumables to enterprise clients fall outside the UCPD, governed instead by Directive 2006/114/EC concerning misleading and comparative advertising, as well as national commercial codes [25].
- MDR and IVDR Article 7. Sector-specific device regulations under Regulation (EU) 2017/745 (MDR) [26] and Regulation (EU) 2017/746 (IVDR) [27] apply a media-neutral prohibition on misleading claims across both professional B2B and consumer B2C promotion.
Directives apply across the 27 EU Member States through national transposing legislation, and Member States retain specific national procedural rules and administrative sanction mechanisms [5].
EmpCo and National Consumer-Protection Measures
Directive (EU) 2024/825 (Empowering Consumers for the Green Transition, known as the EmpCo Directive) amends the Unfair Commercial Practices Directive (2005/29/EC) by inserting specific commercial practices into the blacklist of Annex I [5], [24]. Article 4 required Member States to adopt and publish implementing measures by March 27, 2026, and apply them from September 27, 2026. Traders should check the national measures applicable to each consumer campaign [5], [24].
For consumer-facing medical devices, over-the-counter health products, diagnostic kits, and digital health software, the following Annex I practices are relevant under applicable national implementing measures [24]:
- Annex I Item 2a (Uncertified Sustainability Labels). Displaying a sustainability label with neither a certification scheme nor a public authority behind it is prohibited as a per-se unfair commercial practice [24]. For example, an invented “GreenDevice Certified” badge with neither basis fails this test [24].
- Annex I Item 4a (Generic Environmental Claims). Making a generic environmental claim without substantiated recognised excellent environmental performance relevant to the claim is prohibited [24]. A generic “eco-friendly diagnostic cartridge” claim needs recognised excellent environmental performance relevant to that claim. The routes are the EU Ecolabel under Regulation (EC) No 66/2010, a national or regional EN ISO 14024 type I ecolabelling scheme officially recognised in a Member State, or top environmental performance under other applicable Union law [24]. Recital 10 explains that an unqualified claim such as “sustainable pulse oximeter” also conveys non-environmental characteristics, so evidence of recognised excellent environmental performance alone cannot substantiate that broader claim [24].
- Annex I Item 4b (Environmental Claims on Entire Products). Making an environmental claim about the entire product or the trader's entire business when it concerns only a certain aspect of the product or a specific activity is prohibited [24]. For example, advertising a diagnostic testing unit as environmentally sustainable when only the outer cardboard shipping carton is recyclable violates Item 4b [24].
- Annex I Item 4c (Claims Based on Greenhouse Gas Offsetting). Claiming, based on the offsetting of greenhouse gas emissions, that a product has a neutral, reduced, or positive impact on the environment in terms of greenhouse gas emissions is prohibited [24]. The prohibition covers consumer healthcare device claims such as "carbon neutral" or "climate positive" based on purchased carbon credits [24].
- Annex I Items 23d–23j (Software Updates, Durability and Consumables). Item 23d covers withholding adverse effects of updates on functioning. Item 23e covers calling a feature-only update necessary. Item 23f covers commercial communications about goods with a feature introduced to limit durability when the trader has information about the feature and its effects. Item 23g covers false durability claims under normal use. Item 23h covers falsely presenting a good as repairable. Items 23i and 23j cover premature replacement of consumables and withholding or making false claims about impairment from non-original consumables, parts or accessories [24].
Omnibus Directive (EU) 2019/2161: Review Verification and Penalties
EmpCo operates alongside consumer review provisions introduced by Directive (EU) 2019/2161 (the Modernisation and Omnibus Directive) [5], [23]:
- Annex I Item 23b (Review Verification Duty). Stating that reviews of a product are submitted by consumers who have actually used or purchased the product without taking reasonable and proportionate steps to check that they originate from such consumers is prohibited [23]. Displaying a "Verified Patient Feedback" tag without reasonable and proportionate verification steps violates Item 23b [23].
- Annex I Item 23c (Prohibition on Fake Reviews and Endorsements). Submitting or commissioning another legal or natural person to submit false consumer reviews or endorsements, or misrepresenting consumer reviews or social endorsements, is prohibited [23].
- Material Information on Review Verification (UCPD Article 7(6)). Under Article 7(6) of Directive 2005/29/EC as amended by Directive (EU) 2019/2161, where a trader provides access to consumer reviews of products, information about whether and how the trader ensures that published reviews originate from consumers who have actually used or purchased the product is regarded as material information [23].
- Fine floor in coordinated actions. Where Article 21 of Regulation (EU) 2017/2394 calls for penalties, UCPD Article 13(3) requires Member States to provide for a maximum fine of at least 4% of the trader's annual turnover in the Member States concerned. Article 13(4) sets a maximum of at least EUR 2 million when turnover information is unavailable [23].
Sector-Specific Medical Device Rules: MDR and IVDR Article 7
Independent of general consumer protection law, Article 7 of MDR (EU) 2017/745 [26] and IVDR (EU) 2017/746 [27] governs promotional claims for medical devices and diagnostics. Article 7 applies to labeling, instructions for use, making available, putting into service, and advertising across all media formats, encompassing text, names, trademarks, pictures, and figurative signs [26], [27].
Article 7 prohibits promotional claims that mislead users or patients regarding intended purpose, safety, and performance by [26], [27]:
- Ascribing functions and properties the device lacks (Article 7(a)) [26], [27].
- Creating a false impression regarding treatment or diagnosis, functions, or properties the device lacks (Article 7(b)) [26], [27].
- Failing to inform the user or the patient of a likely risk associated with the use of the device in line with its intended purpose (Article 7(c)) [26], [27].
- Suggesting uses for the device other than those stated to form part of the intended purpose for which the conformity assessment was carried out (Article 7(d)) [26], [27].
Unlike UCPD rules, Article 7 applies equally to professional B2B clinical materials and B2C communications [26], [27]. When promotional videos depict clinical procedures without presenting likely risks (Article 7(c)) or suggest uncertified applications (Article 7(d)), national competent authorities may initiate market surveillance corrective actions, request marketing withdrawal, or impose administrative sanctions under national law [26], [27].
The Digital Services Act (Regulation (EU) 2022/2065) and Website Privacy
Commercial digital advertising across social platforms inside the European Union intersects with platform governance under the Digital Services Act (Regulation (EU) 2022/2065) [28]:
- Platform Ad Transparency (Article 26(1)). Online platform providers must ensure that ad recipients can identify in real time that the information is an advertisement, the person on whose behalf it is presented, and the person who paid for it [28]. Life sciences advertisers encounter this requirement through platform disclosure tools for paid posts and corporate sponsorships [28].
- Prohibition on Special-Category Health Profiling (Article 26(3)). Article 26(3) prohibits online platforms from presenting advertisements to recipients based on profiling using special categories of personal data referred to in Article 9(1) of the GDPR, which explicitly encompasses data concerning health, genetic data, and biometric data [28]. VayoMed recommends that commercial marketing teams structure campaign targeting parameters to exclude inferred or declared health conditions [28].
- Website Tracking and Consent. Under applicable national implementation of ePrivacy Article 5(3), storing information on or accessing information from terminal equipment requires consent unless an exemption applies. Assess that rule for third-party tracking pixels [30]. Separately, where processing reveals a person’s health status, the controller needs a GDPR Article 6 lawful basis and an applicable Article 9(2) condition. Where the controller relies on consent for the described marketing use, Article 9(2)(a) requires explicit consent for the specified purpose [29].
A Pre-Publication Review Workflow for Life Sciences Commercial Assets
Translating multi-jurisdictional statutory requirements into commercial operations requires distinguishing mandatory legal baselines from recommended review practices. A review system must define what the law requires for each product class and format, alongside prudent operational controls.
Evidence varies by channel. Use a time-coded parity sheet for a covered TV spot, documented use and typicality evidence for a testimonial, and a briefing record for executive media.
| Channel & Media Format | Product Class Scope | Binding Provision | Guidance or Letter Position (Nonbinding) | Suggested Pre-Publication Evidence | Recommended Review Gate |
|---|---|---|---|---|---|
| Executive & Clinician Podcasts / Media Appearances | Prescription drugs, biologics, medical devices, and IVDs | Statements by representatives may establish objective intent (21 CFR §§ 801.4, 201.128); Form FDA 2253 filing for drug promotional materials disseminated by sponsor (21 CFR § 314.81(b)(3)(i)) | FTC Guides § 255.5 addresses material connections. ImmunityBio discusses an executive podcast that was accessible from the company site. | Pre-interview briefing transcript, cleared indication boundary guide, and signed speaker conflict-of-interest disclosure log | MLR pre-clearance prior to appearance; editorial rule prohibiting corporate website embeds or direct hyperlinks to third-party media discussing unapproved uses |
| Patient & Clinical Customer Testimonials | Medical devices, IVDs, OTC diagnostics, and prescription products (US only) | Prohibitions on fake reviews/testimonials (FTC 16 CFR § 465.2); employee connection disclosures (§ 465.5); EU review verification (Omnibus Item 23b & UCPD Art 7(6)); device intended use (21 CFR § 801.4) | FTC Guides § 255.2(b) addresses generally expected performance. Evolus addresses a variation subtitle, and Agena addresses customer stories as evidence of use. | Documented proof of product use, signed testimonial release, typicality evidence, and privacy sign-off and any authorization or consent it requires. | MLR validation that depicted patient experiences align with cleared labeling; mandate prominent disclosure of generally expected performance; ban sentiment-conditioned incentives |
| DTC Broadcast Television Commercials | Direct-to-consumer prescription drugs and licensed biologics | Mandatory dual-modality major statement (21 CFR § 202.1(e)(1)(ii)(C)); non-distracting audio/visual pacing (Standard E); Form FDA 2253 postmarketing submission (21 CFR § 314.81(b)(3)(i), 21 CFR § 601.12(f)(4)) | FDA Small Entity Compliance Guide gives examples of concurrent verbatim text. Vanda and Wegovy cite discrepancies between the audio and the text. | Time-coded audio-SUPER verbatim parity audit sheet, typographic contrast verification report, and audio volume/pacing analysis | Dual-modality verbatim alignment sign-off by regulatory lead; distraction audit of background music and visual action cuts; eCTD Form FDA 2253 submission at initial broadcast |
| Social Media Video Reels & Feed Ads | Prescription drugs, biologics, medical devices, and consumer health products | FD&C Act § 502 and 21 CFR § 202.1(e) for advertising in scope. FTC Act § 5 where applicable. | FTC Guides § 255.0(f) addresses disclosure in both audio and visual portions. Evolus and Ozempic discuss the timing and prominence of risk information. | Storyboard verifying indication and risk placement upstream of platform caption folds; verified script captions matching audio; substantiated typicality data | Self-contained container review ensuring safety information is visible within the active video frame without relying on trailing captions, hashtags, or external link directives |
| EU Consumer Digital Marketing & Web Portals | Consumer medical devices, OTC diagnostics, and digital health software (B2C) | EmpCo Annex I items 2a, 4a–4c and 23d–23j under applicable national measures. Directive 2001/83/EC Article 88(1)(a) for advertising prescription drugs to the public. | None cited for this channel. | Certification documentation where needed, substantiation for durability claims and records of the intended audience. | Check consumer-facing copy for sustainability labels, green claims and offset-based claims. Check applicable local transposition. |
| Corporate Websites & Campaign Microsites | All life sciences product portfolios | FDA misbranding provisions and FTC Act § 5 within their respective scopes. IVD labeling under 21 CFR § 809.10(c) and MDR/IVDR Article 7 where applicable. | Agena, Estar and Anne’s Daye identify company web pages as evidence. Sprout identifies an executive’s personal post. | Reviewed URLs and final creative, with applicable authorized claim references. | Open and compare landing pages, executive posts and linked media before approving the campaign. |
VayoMed editorial framework based on FTC 16 CFR Parts 255 & 465, FDA 21 CFR § 202.1(e)(1) & § 801.4, EU Directives 2001/83/EC & (EU) 2024/825, and Regulations (EU) 2017/745 & (EU) 2017/746.
Six Core Controls for Digital, Video, and Endorsement Review
Control 1: Testimonial and Customer Story Integrity Pipeline
- Binding legal duty. Under 16 CFR § 465.2, a business may not write, create or sell a fake consumer review, consumer testimonial or celebrity testimonial. The rule also covers buying a consumer review or disseminating a consumer or celebrity testimonial that the business knew or should have known was fake [1]. Apply the three § 465.5 tests in the Part 465 table. The otherwise-clear exception in paragraph (a) is for testimonials. Paragraph (b) covers a business disseminating an insider’s undisclosed testimonial when the relationship is otherwise unclear and the business knew or should have known of it. Paragraph (c) covers an officer’s or manager’s solicitation that results in an undisclosed insider review under the conduct conditions in the table [1]. Under EU Omnibus Directive Annex I Item 23b, stating that reviews originate from actual consumers requires reasonable and proportionate verification [23]. Under UCPD Article 7(6), information regarding review verification processes is material [23]. Under FDA 21 CFR § 801.4, statements in customer testimonials published on device websites may be used as evidence of intended use [21], as demonstrated in the Agena warning letter [42].
- Agency guidance and letter positions. Under FTC Endorsement Guides 16 CFR § 255.2(b), the advertiser should substantiate that the depicted experience is representative. Otherwise, clearly and conspicuously disclose the substantiated, generally expected performance in the depicted circumstances. Example 2 in § 255.2(e) describes disclaimers about the limited applicability of an endorser’s experience as “unlikely to be effective” [10]. In Evolus, OPDP stated that an "Individual results may vary" visual subtitle did not mitigate the misleading impression created by the post [13].
- VayoMed recommendation. Implement documented user verification (such as affirmative order records or clinical use confirmation) before displaying customer testimonials. Require endorsers to sign user-authenticity attestations confirming they received no compensation conditioned on review sentiment. Maintain an internal log of unedited ratings. Verify that customer quotes describe outcomes aligned with cleared labeling or CE-marked technical documentation [42].
- Privacy review. This report does not survey the privacy rules for patient stories. Before confirming patient status or publishing a patient's story, ask the privacy team to determine the permissions needed. Examples include a HIPAA authorization where a covered entity supplies the information and an applicable basis under GDPR Article 9, such as explicit consent [29] [47].
Control 2: Dual-Modality Video and Social-Reel Review
- Binding legal duty. Under FDA 21 CFR § 202.1(e)(1)(ii)(C), television-format direct-to-consumer prescription drug advertisements must present the major statement concurrently in both audio and visual text, displaying either the verbatim complete transcript or verbatim key terms or phrases (the same words, not synonyms) [4], [11]. Under § 202.1(e)(1)(ii)(E), the major statement must be free of audio or visual elements likely to interfere with its comprehension [4], [11]. Under 21 CFR § 314.81(b)(3)(i) [19] and 21 CFR § 601.12(f)(4) [20], prescription drug and biologic promotional video must be submitted under cover of Form FDA 2253 at initial dissemination.
- Agency guidance and letter positions. Under FTC 16 CFR § 255.0(f), video endorsements that make a representation visually and audibly should disclose the material connection in both portions. The Guides say simultaneous presentation is more likely to be clear and conspicuous [10]. In Evolus, OPDP said risks shown only after the tagline and a black screen lacked prominence and readability reasonably comparable to the benefit presentation [13]. In Pfizer, OPDP noted that placing full indications after an ISI block was not sufficient to correct misleading indication claims in the main video creative [14].
- VayoMed recommendation. VayoMed recommends a timed text-and-audio comparison for every promotional video that carries risk information. Outside television or radio format, the firm decides how far to apply this internal benchmark. Use time-coded review sheets to verify exact correspondence between spoken voiceovers and visual SUPER text. During risk presentations, avoid rapid editorial scene cuts or dramatic musical crescendos [12], [17]. Place approved indications and boxed warnings within the primary video frame upstream of platform caption folds [13]. Use reviewed, verified captions matching the approved script rather than unverified platform auto-captions.
Control 3: Executive, KOL, and External Media Appearance Gate
- Binding legal duty. Under FDA 21 CFR § 801.4 and § 201.128, oral or written statements made by company officers, medical directors, and authorized representatives may be evaluated by FDA as objective evidence of intended use [21], as seen in the ExThera, Anne's Daye, and Agena warning letters [42], [43], [44]. Under 21 CFR § 314.81(b)(3)(i), promotional assets disseminated or promoted by a drug sponsor must be submitted under Form FDA 2253 [19].
- Agency guidance and letter positions. Under FTC 16 CFR § 255.5, material connections between expert endorsers and the sponsor must be disclosed if not reasonably expected by the audience [10]. In ImmunityBio, OPDP issued a warning letter citing Dr. Soon-Shiong's statements on an external video podcast that could also be accessed through the company’s website as establishing unapproved new uses and failing Form FDA 2253 submission requirements [38].
- VayoMed recommendation. Establish mandatory pre-clearance briefing sheets for executives and clinicians participating in podcasts, investor interviews, and industry conferences. Brief speakers on cleared indications and prohibited off-label discussions. Prohibit corporate websites and branded social channels from publishing direct hyperlinks or video embeds to third-party media containing off-label or unapproved claims [38], [40].
Control 4: Medical Device and IVD Intended-Use Verification
- Binding legal duty. A device promoted for an intended use outside its clearance or approval may be adulterated under FD&C Act § 501(f)(1)(B) and misbranded under § 502(o) [9] [21] [48]. MDR and IVDR Article 7 also govern claims about intended purpose, safety and performance where those rules apply [26] [27].
- Agency guidance and letter positions. Agena customer stories described clinical diagnosis using an RUO platform. ExThera media represented an investigational device as safe and effective. Anne's Daye promoted pain relief for tampons cleared as non-medicated, and Estar's websites promoted uses outside its PRP systems' clearance [42] [43] [44] [45].
- VayoMed recommendation. Maintain a canonical claim registry linking every web page, brochure, and customer case study to its specific clearance identifier. Enforce navigational separation between Research Use Only instrument subfolders and clinical laboratory diagnostic workflows [42].
Control 5: European Union B2C Claim and Sustainability Hygiene
- Binding legal duty. Apply the national measures implementing EmpCo. Check the specific practices listed in the EmpCo subsection, including sustainability labels that have neither a certification scheme nor public-authority establishment (Item 2a), and whole-product or whole-business environmental claims supported only for one aspect or activity (Item 4b). The subsection also covers generic and offset-based claims (Items 4a and 4c). Items 23d–23j cover specified update disclosures and representations, commercial communications involving a known durability-limiting feature, false durability or repairability representations, premature consumable replacement, and specified claims or omissions about impairment from non-original consumables, parts or accessories [24]. Member States must prohibit public advertising of prescription-only medicines under Directive 2001/83/EC Article 88(1)(a) [22]. Apply the terminal storage or access consent rule and its exemptions separately from the Article 6 basis and Article 9(2) condition for personal health-data processing. See Website Tracking and Consent for the explicit-consent route where relied on for marketing [29] [30].
- VayoMed recommendation. Audit EU-facing consumer domains to remove unverified eco-badges, generic green claims, and carbon-offset phrasing. Ensure that B2B technical specifications are clearly segregated from consumer marketing. Deploy cookie consent mechanisms that hard-block non-essential analytics and tracking pixels prior to explicit user affirmative consent.
Control 6: Check the Claims Across Linked Assets
- Binding legal duty. FDA misbranding provisions govern labeling and prescription-drug or restricted-device advertising within their scope. Section 5 of the FTC Act applies to deceptive advertising within FTC jurisdiction [8] [9] [49].
- Agency guidance and letter positions. CDRH or CBER cited company web pages in Agena, Estar and Anne's Daye. OPDP cited a personal executive account in Sprout [42] [45] [44] [39].
- VayoMed recommendation. Determine the role of each page or asset from its use in the campaign. Open each landing page, linked external asset and executive post as the audience will see it. Compare the final claims with the signed claim inventory and retain the reviewed URL and version so the team can reproduce the review after a change.
Evidentiary Limits and Strongest Counterarguments
A balanced assessment of commercial life sciences advertising law requires examining the legal limitations of available evidence and addressing several significant counterarguments:
- Should every video with risk information get a timed check? Evolus, Pfizer and Ozempic drew letters that did not cite the CCN standards [13] [14] [15]. A covered television-format ad remains subject to the rule when shown online [4]. Vanda and Wegovy had on-screen risk text the voiceover did not carry. One timed review per asset can identify that mismatch in any format [12] [16]. A firm that limits this check to television-format assets should document each classification.
- Does the 2025 spike show a lasting rise in letters? The sharp rise in OPDP untitled letters in 2025 (63 letters vs. 5 in 2024) might suggest an organic twelve-fold acceleration across all promotion [6]. However, 52 of those 63 letters (82.5%) were issued on a single date—September 9, 2025—to brand-name prescription drug sponsors (including AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Novartis, Pfizer, Altor BioScience, and Evolus) as part of a coordinated enforcement sweep [6], [7]. While that batch demonstrates agency capacity for coordinated surveillance against brand sponsors, it was a single event. The 25 letters recorded through October 26, 2026 already exceed every full-year total from 2017–2024 [6].
- Does the Consumer Review Rule impose a uniform knowledge standard? Its provisions carry different elements. Section 465.2(b)–(c) requires that the business knew or should have known of the material misrepresentation, and § 465.8 addresses knowledge of falsity for the specified social indicators [1]. Section 5(m)(1)(A) imposes a separate knowledge requirement for civil penalties [2] [49]. The FTC's December 22, 2025 letters were staff warnings about potential violations [32].
- Should institutional materials go through the EU consumer checklist? EmpCo and Omnibus amend the UCPD for business-to-consumer practices [23] [24]. For hospital or laboratory marketing, assess Article 7 of the device regulations and Directive 2006/114/EC alongside applicable national law [26] [27] [25].
- Is an MLR sign-off enough? FDA letters to major sponsors describe materials under review and provide no view of their internal approval process. The Evolus caption fold and the Pfizer indication after the safety block illustrate why VayoMed recommends inspecting the actual rendered creative in addition to recording the approval [13] [14].
Strategic Recommendations and Conclusion
Managing promotional compliance across testimonials, KOL videos, and digital marketing assets requires systematic execution across four core principles:
- Set the review criteria by format. VayoMed recommends recording the product class, audience, format and final distribution channel. Covered television and radio ads must meet the CCN rule, with concurrent audio and text required for television format [4] [11]. Assess the applicable initial-dissemination submission rules for drugs and biologics separately [19] [20].
- Substantiate the expected outcome. Apply the FTC Guides’ typicality analysis and consider the staff FAQ’s examples of disclaimers that leave the overall impression intact [10] [33]. In Evolus, OPDP said the variation subtitle did not mitigate the misleading impression [13].
- Review executive and KOL media before distribution. Have MLR review the intended-use implications of the interview, the company’s links and captions, and the relevant submission duties. ImmunityBio and Sprout illustrate how external or personal channels can enter an FDA review [38] [39].
- Separate EU B2C marketing from institutional collateral. When reviewing consumer-facing EU material, apply the national prescription-medicine advertising prohibition and the relevant EmpCo implementing measures. The detailed EmpCo subsection covers when sustainability labels, environmental claims, update statements and durability or repairability representations are prohibited [22] [24]. Route institutional claims through the applicable device and B2B review [5] [26] [27].
Where an Execution Partner Fits: Operational Infrastructure and Client MLR Authority
For growing medical device, diagnostic, and biopharma companies expanding across international markets, implementing multi-channel digital publishing infrastructure requires substantial technical coordination [50]. VayoMed provides commercial publishing and distribution infrastructure through a 12-month Done-for-You subscription ($24,000/year, equivalent to $2,000/month) [50]. VayoMed works across 40+ international markets [50]. Infrastructure deliverables include global website builds, ongoing website maintenance, corporate LinkedIn management, domain portfolio administration, source-grounded content production, and monthly press release distribution syndicated via PR Newswire, Yahoo Finance, Morningstar, and 50+ partner platforms [50].
Authority & Governance Boundary. VayoMed operates strictly as the commercial engineering, content operations, and distribution infrastructure partner [50]. The client retains exclusive Medical, Legal, and Regulatory (MLR) review and final sign-off authority over every product claim, video script, testimonial release, clinical disclosure, and regulatory filing [50]. VayoMed does not guarantee regulatory product clearances, search-engine rankings, commercial leads or editorial pickup after distribution [50].
Methodology and Public Record Scope
The findings in this study reflect public compliance and regulatory records examined during primary research:
- FDA OPDP Untitled Letters. Public index records from CDER OPDP spanning calendar years 2017 through October 26, 2026 (n = 120 total letters) were reviewed directly to confirm annual letter volumes and the September 9, 2025 batch [6].
- Enforcement Letter Full Texts. Specific warning letters and untitled letters cited across OPDP, CBER, and CDRH were examined in full text from official FDA compliance repositories, verifying quoted statements, asset formats, and cited statutory provisions [12], [13], [14], [15], [16], [17], [38], [39], [40], [41], [42], [43], [44], [45]. The fourteen letters were chosen to illustrate video, social, executive-media, customer-story and website formats. The provision comparisons apply to those letters alone.
- Statutory and regulatory texts. Sources link to the Federal Register, eCFR, GovInfo and the U.S. Code for U.S. provisions. The EU references use EUR-Lex for the Unfair Commercial Practices Directive, EmpCo, the medicinal-product advertising directive, the MDR, IVDR, Digital Services Act, GDPR, ePrivacy Directive and the B2B advertising directive [22] [23] [24] [26] [27] [28] [29] [30] [25].
- Limitations. The letters are advisory, as described in the case introduction [36]. Company responses and later close-out decisions were outside the scope. EU transposition and enforcement procedures vary by Member State.
Sources
1. U.S. Federal Trade Commission, Trade Regulation Rule on the Use of Consumer Reviews and Testimonials (16 CFR Part 465), Final Rule, 89 FR 68034
2. U.S. Federal Trade Commission, Adjustments to Civil Penalty Amounts (16 CFR § 1.98(d)), Final Rule, 90 FR 5580
3. U.S. Federal Trade Commission, Civil Penalty Inflation Adjustments, Notice, 91 FR 58446
4. U.S. Food and Drug Administration, Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format (21 CFR § 202.1(e)(1)), Final Rule, 88 FR 80958
5. European Commission, Directorate-General for Justice and Consumers, Unfair Commercial Practices Directive (2005/29/EC) Legal Overview
6. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, OPDP Untitled Letters Index (2017 through October 26, 2026)
7. U.S. Food and Drug Administration, Press Announcement: FDA Launches Crackdown on Deceptive Drug Advertising (September 9, 2025)
8. U.S. Food and Drug Administration and U.S. Federal Trade Commission, Memorandum of Understanding Between the Federal Trade Commission and the Food and Drug Administration (MOU 225-71-8003)
9. U.S. Government Publishing Office, United States Code, Title 21, Section 352 (FD&C Act § 502, Misbranded Drugs and Devices)
10. U.S. Federal Trade Commission, Guides Concerning the Use of Endorsements and Testimonials in Advertising (16 CFR Part 255), Revised Final Guides, 88 FR 48092
11. U.S. Food and Drug Administration, Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner: Questions and Answers — Small Entity Compliance Guide (88 FR 89303, December 2023)
12. U.S. Food and Drug Administration, Office of Prescription Drug Promotion, Untitled Letter to Vanda Pharmaceuticals, Inc. (NDA 220152, NEREUS, October 26, 2026)
13. U.S. Food and Drug Administration, Office of Prescription Drug Promotion, Untitled Letter to Evolus, Inc. (BLA 761085, JEUVEAU, September 28, 2026)
14. U.S. Food and Drug Administration, Office of Prescription Drug Promotion, Untitled Letter to Pfizer, Inc. (BLA 125388, ADCETRIS, April 8, 2026)
15. U.S. Food and Drug Administration, Office of Prescription Drug Promotion, Untitled Letter to Novo Nordisk Inc. (NDA 209637, OZEMPIC, February 26, 2026)
16. U.S. Food and Drug Administration, Office of Prescription Drug Promotion, Untitled Letter to Novo Nordisk Inc. (NDA 218316, WEGOVY, February 5, 2026)
17. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Warning Letter 716297 to CSL Behring (BLA 125350/1472, HIZENTRA, September 9, 2025)
18. Electronic Code of Federal Regulations, 21 CFR § 202.1, Prescription-drug advertisements
19. National Archives and Records Administration, Electronic Code of Federal Regulations, 21 CFR § 314.81 (Other Postmarketing Reports, Form FDA 2253)
20. National Archives and Records Administration, Electronic Code of Federal Regulations, 21 CFR § 601.12(f)(4) (Biologics Postmarketing Promotional Labeling, Form FDA 2253)
21. U.S. Food and Drug Administration, Regulations Regarding Intended Uses (21 CFR § 801.4 and 21 CFR § 201.128), Final Rule, 86 FR 41383
22. European Parliament and Council of the European Union, Directive 2001/83/EC of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use (Title VIII Advertising)
23. European Parliament and Council of the European Union, Directive 2005/29/EC of 11 May 2005 Concerning Unfair Business-to-Consumer Commercial Practices in the Internal Market (Consolidated Text)
24. European Parliament and Council of the European Union, Directive (EU) 2024/825 of 28 February 2024 Amending Directives 2005/29/EC and 2011/83/EU as Regards Empowering Consumers for the Green Transition
25. European Parliament and Council, Directive 2006/114/EC concerning misleading and comparative advertising
26. European Parliament and Council of the European Union, Regulation (EU) 2017/745 of 5 April 2017 on Medical Devices (MDR, Article 7 Claim Prohibitions)
27. European Parliament and Council of the European Union, Regulation (EU) 2017/746 of 5 April 2017 on In Vitro Diagnostic Medical Devices (IVDR, Article 7 Claim Prohibitions)
28. European Parliament and Council of the European Union, Regulation (EU) 2022/2065 of 19 October 2022 on a Single Market For Digital Services (Digital Services Act, Article 26)
29. European Parliament and Council of the European Union, Regulation (EU) 2016/679 on the Protection of Natural Persons with Regard to the Processing of Personal Data (GDPR, Articles 6 and 9)
30. European Parliament and Council of the European Union, Directive 2002/58/EC Concerning the Processing of Personal Data and the Protection of Privacy in the Electronic Communications Sector (ePrivacy Directive, Article 5(3))
31. U.S. Federal Trade Commission, Business Guidance: Consumer Reviews and Testimonials Rule Questions and Answers
32. U.S. Federal Trade Commission, Press Release: FTC Warns 10 Companies About Possible Violations of Agency's New Consumer Review Rule (December 22, 2025)
33. U.S. Federal Trade Commission, Staff Business Guidance: The FTC's Endorsement Guides: What People Are Asking (Staff FAQ)
34. U.S. Federal Trade Commission, Health Products Compliance Guidance (December 2022)
35. Unified Agenda of Federal Regulatory and Deregulatory Actions, RIN 0910-AJ14, Transparency in Direct-to-Consumer Advertising (HHS/FDA, proposed rule stage)
36. U.S. Food and Drug Administration, Regulatory Procedures Manual, Chapter 4: Advisory Actions (Warning Letters and Untitled Letters)
37. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Bad Ad Program (Surveillance of Truthful Prescription Drug Promotion)
38. U.S. Food and Drug Administration, Office of Prescription Drug Promotion, Warning Letter 725468 to ImmunityBio, Inc. (BLA 761336, ANKTIVA, March 13, 2026)
39. U.S. Food and Drug Administration, Office of Prescription Drug Promotion, Warning Letter 709942 to Sprout Pharmaceuticals, Inc. (NDA 022526, ADDYI, May 29, 2025)
40. U.S. Food and Drug Administration, Office of Prescription Drug Promotion, Warning Letter 626957 to CytoDyn, Inc. (IND Leronlimab, February 11, 2022)
41. U.S. Food and Drug Administration, Office of Prescription Drug Promotion, Warning Letter 613339 to CooperSurgical, Inc. (NDA 018680, Paragard, February 12, 2021)
42. U.S. Food and Drug Administration, Center for Devices and Radiological Health, Warning Letter 665159 to Agena Bioscience, Inc. (MassARRAY4 IVD, March 21, 2024)
43. U.S. Food and Drug Administration, Center for Devices and Radiological Health, Warning Letter 715068 to ExThera Medical Corporation (IDE G210074 / G230144, February 6, 2026)
44. U.S. Food and Drug Administration, Center for Devices and Radiological Health, Warning Letter 696362 to Anne's Daye Ltd d/b/a Tampon Innovations (December 17, 2024)
45. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Warning Letter 716831 to Estar Technologies Ltd (510(k) BK110035, April 22, 2026)
46. U.S. Food and Drug Administration, Addressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers, Draft Guidance for Industry (89 FR 56387, July 2024)
47. U.S. Department of Health and Human Services, Marketing under the HIPAA Privacy Rule
48. U.S. Code, Title 21, Section 351 (FD&C Act § 501, Adulterated Drugs and Devices)
49. U.S. Code, Title 15, Section 45 (FTC Act § 5)
50. VayoMed, 12-Month Done-for-You Global Growth Engine for Life Sciences Commercial Teams

Founder @ VayoMed, RAC
DJ is a Regulatory Affairs Certified (RAC) professional with deep expertise in life sciences go-to-market strategy. He helps medical device and healthcare companies navigate the intersection of regulatory compliance and digital visibility, ensuring brands are positioned for success in both traditional and AI-powered search environments.
Need the engine that comes after clearance?
VayoMed builds and runs your website, content, LinkedIn, domains, PR, and AI visibility as one fully managed $24K/year annual subscription.
